Raltegravir once daily or twice daily in previously untreated patients with HIV-1: A randomised, active-controlled, phase 3 non-inferiority trial

The Lancet Infectious Diseases

Volumn 11, Issue 12, 2011, Pages 907-915

  Eron, Joseph J ^a   Rockstroh, Jürgen K ^b   Reynes, Jacques ^c   Andrade Villanueva, Jaime ^d   Ramalho Madruga, Jose Valdez ^e   Bekker, Linda Gail ^f   Young, Benjamin ^g   Katlama, Christine ^h   Gatell Artigas, Jose Maria ⁱ   Arribas, Jose R ^j   Nelson, Mark ^k   Campbell, Havilland ^l   Zhao, Jing ^b   Rodgers, Anthony J ^b   Rizk, Matthew L ^b   Wenning, Larissa ^b   Miller, Michael D ^b   Hazuda, Daria ^b   DiNubile, Mark J ^b   Leavitt, Randi ^b   Isaacs, Robin ^b   Robertson, Michael N ^b   Sklar, Peter ^b   Nguyen, Bach Yen ^b   more..

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c GUI DE CHAULIAC HOSPITAL   (France)

^d UNIVERSITY OF GUADALAJARA   (Mexico)

^e Centro de Referencia e Treinamento DST/AIDS   (Brazil)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g Rocky Mountain CARES/Denver Infectious Disease Consultants   (United States)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^k Crusaid Research Institute   (United Kingdom)

^l MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; RALTEGRAVIR; VIRUS RNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BRONCHITIS; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTENSION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; VOMITING;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PYRROLIDINONES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 81855166275     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70196-7     Document Type: Article

References (28)

1. Espeseth AS, Felock P, Wolfe A, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA 2000, 97:11244-11249.
2. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287:646-650.
3. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004, 305:528-532.
4. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008, 359:355-365. the BENCHMRK Study Teams.
5. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008, 359:339-354. the BENCHMRK Study Teams.
6. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369:1261-1269. the Protocol 005 Team.
7. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007, 46:125-133. the Protocol 004 Part II Study Team.
8. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009, 52:350-356. the Protocol 004 Part II Study Team.
9. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009, 374:796-806. the STARTMRK investigators.
10. Lennox JL, DeJesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010, 55:39-48. the STARTMRK Investigators.
11. Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2008, 52:3253-3258.
12. Flexner C, Tierney C, Gross R, et al. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis 2010, 50:1041-1052. the ACTG A5073 Study Team.
13. Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr 2009, 50:474-481.
14. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010, 53:323-332. the CASTLE Study Team.
15. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents DHHS Panel-Office of AIDS Research Advisory Council (OARAC), (accessed Feb 22, 2011). http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
16. Moltó J, Valle M, Back D, et al. Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients. Antimicrob Agents Chemother 2011, 55:72-75.
17. Wenning L, Hwang E, Nguyen B-Y, et al. Pharmacokinetic/pharmacodynamic (PK/PD) analyses for raltegravir (RAL) in phase III studies in treatment experienced HIV-infected patients following 48 weeks of treatment. Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Infectious Diseases Society of America; Washington, DC, USA; Oct 25-28, 2008: abstr H-4054.
18. McSharry J, Weng Q, Zager K, Soldani K, Kulawy R, Drusano G. Pharmacodynamics of raltegravir, an HIV integrase inhibitor, in an in vitro hollow fiber infection model system. Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Infectious Diseases Society of America; Washington, DC, USA; Oct 25-28, 2008: abstr A-960.
19. Grobler JA, McKenna PM, Ly S, et al. HIV integrase inhibitor dissociation rates correlate with efficacy in vitro. 18th International HIV Drug Resistance Workshop. Antivir Ther 2009, 14(suppl 1):A27.
20. Miettinen O, Nurminen M Comparative analysis of two rates. Stat Med 1985, 4:213-226.
21. Hirschel B, Calmy A Initial treatment for HIV infection-an embarrassment of riches. N Engl J Med 2008, 358:2170-2172.
22. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008, 372:646-655. the CASTLE Study Team.
23. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008, 22:1389-1397.
24. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009, 50:367-374.
25. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009, 23:1547-1556. the HEAT study team.
26. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009, 361:2230-2240. the AIDS Clinical Trials Group Study A5202 Team.
27. Shen L, Peterson S, Sedaghat AR, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008, 14:762-766.
28. Lubomirov R, Colombo S, di Iulio J, et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis 2011, 203:246-257. the Swiss HIV Cohort Study.